Dr. med. vet. Weibo Kong
Publikationen
Packeiser, E.; Taher, L.; Kong, W.; Ernst, Mathias; Beck, U.; Hewicker-Trautwein, M.; Brenig, B.; Schütz, E.; Murua Escobar, H.; Nolte, I. (2022):
RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. CANCER CELL INT
22: 54, 1-21
Ma, Y.; Sender, G.; Sekora, A.; Kong, W.; Bauer, Peter; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-ali, R.; Weiss, Frank Ulrich; Lerch, M.; Parveen, A.; Zechner, Dietmar; Junghanss, C.; Murua Escobar, H. (2022):
Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Int J Mol Sci 23 (8): 4409, 1-17
Ma, Y; Sender, G.; Sekora, A.; Kong, W.; Bauer, Peter; Ameziane, N.; Ruslan, A.; Krake, S.; Radefeldt, M.; Weiss, Frank-Ulrich; Lerch, M.; Parveen, A.; Junghanss, C.; Murua Escobar, H. (2022):
The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Int J Mol Sci 23 (8): 4295, 1-16
Kong, W.; Sender, G.; Taher, L.; Villa-Perez, S.; Ma, Y.; Sekora, A.; Ruetgen, B. C.; Brenig, B.; Beck, U.; Schütz, E.; Junghanns, C.; Nolte, I.; Murua Escobar, H. (2021):
BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells. Int J Mol Sci 22 (23): 12673, 1-16
https://doi.org/10.3390/ijms222312673